B of A Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $400
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Ying Huang maintains a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $350 to $400.
July 21, 2023 | 4:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities maintains a Buy rating on Vertex Pharmaceuticals and raises the price target from $350 to $400.
The raised price target by B of A Securities indicates a positive outlook for Vertex Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term as it signals the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100